Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Induction and maintenance doses

From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

  First induction dose Second induction dose Maintenance dose
Ustekinumab Weight based (IV): < 55 kg: 260 mg week 0
> 55 and < 85 kg: 390 mg week 0
> 85 kg: 520 mg week 0, response assessed at week 6
Additional 90 mg dose week 8, response assessed week 16 (SC) 90 mg every 12 weeks (SC)
Adalimumab 160 mg at week 0, 80 mg at week 2 (SC), response assessed at week 4 40 mg dose through week 12 (SC) 40 mg every 2 weeks (SC)
Vedolizumab 300 mg at weeks 0, 2 and 6 (IV), response assessed at week 10 Additional dose week 10, response assessed week 14 (IV) 300 mg every 8 weeks (IV)
  1. IV intravenous, SC subcutaneous